Alendronate sodium is under clinical development by BioRest and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Alendronate sodium’s likelihood of approval (LoA) and phase transition for Coronary Stenosis took place on 20 Apr 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 20 Apr 2022 decreased Alendronate sodium’s LoA and PTSR for Diabetes.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Alendronate sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Alendronate sodium overview
Alendronate sodium (LABR-312) is under development for the treatment of coronary artery stenosis (reducing stenosis at the time of percutaneous coronary intervention) and diabetes mellitus. The therapeutic candidate is a liposomal formulation administered through intravenous route. Alendronate is a nitrogen-containing, second generation bisphosphonate (BP).
Quick View Alendronate sodium LOA Data
|Highest Development Stage|